BRISTOL-MYERS SQUIBB IRELAND UNLIMITED COMPANY Vs. MICRO LABS LIMITED

JUDGEMENT

(1.) This hearing is conducted through video conferencing. IA No.7681/2021

(2.) The accompanying suit is filed for permanent injunction to restrain infringement of the suit patent, disclosure & delivery, damages, etc. It is the case of the plaintiffs that the patent in question was granted in favour of plaintiff No. 1 which relates generally to lactam-containing compounds and derivatives thereof which are inhibitors of trypsin-like serine protease enzymes, especially Factor Xa, pharmaceutical compositions containing the same, and methods of using the same as anticoagulant agents for treatment, of thromboembolic disorders is called "Apixaban". It has been pointed out that the suit patent has not been subjected to any pre-grant or post grant opposition under Section 25(1) and 25(2) of the Patents Act. One Natco Pharma Ltd. had filed a petition seeking revocation of the said suit patent on 09.05.2016 which is pending adjudication. Revocation petitions have also been filed by BDR Pharmaceuticals International Pvt. Ltd. on 17.12.2019 and Micro Labs Ltd., the defendant herein, recently.

(3.) The said suit patent covers, a molecule having an International Non-Proprietary Name (INN) APIXABAN assigned to the molecule and the IUPAC name 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1- yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c] pyridine-3-carboxamide. It is used for the prevention and treatment of thromboembolic diseases. The empirical formula APIXABAN is C17H22N2O6S2. APIXABAN has the following structural formula: